Did You Know...
...that the Eveready Battery began as an invention called the "electric flowerpot," which was a tube with a battery and light bulb inside? The idea was to fasten this gizmo to the side of a flowerpot so it would illuminate the flowers from the bottom. The idea died on the vine and the businessman who licensed the flower pot, Conrad Huber, was left with a pile of useless tubes -- until he found a way to market them as batteries to light the world!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8093363 | Tumor necrosis factor-gamma Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular gro... | 01/10/2012 |
| 8063188 | Anti-myostatin antibodies Monoclonal anti-myostatin antibodies that preferentially bind myostatin over GDF-11, have strong binding affinity to myostatin and are resistant to chemical degradation. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, ... | 11/22/2011 |
| 8026344 | Targeted binding agents directed to uPAR and uses thereof Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain i... | 09/27/2011 |
| 7994293 | Antibodies specific for Dkk-1 Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone ... | 08/09/2011 |
| 7982017 | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein ... | 07/19/2011 |
| 7977464 | Antibody molecules specific to human tumour necrosis factor alpha There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA ... | 07/12/2011 |
| 7935795 | Human monoclonal antibody binding to hGM-CSF and its antigen binding portion The present invention provides a human monoclonal antibody, and antigen-binding portions thereof, capable of binding to human granulocyte-macrophage colony stimulating factor (hGM-CSF) and neutralizing the bioactivity of the hGM-CSF, wherein the anti-hGM-CSF monoclo... | 05/03/2011 |
| 7932363 | Antibody that binds human eosinophil-derived basic protein The present invention provides a human eosinophil-derived basic protein (EBPH) and polynucleotides which identify and encode EBPH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding EBP... | 04/26/2011 |
| 7915391 | Humanized c-Kit antibody This invention relates to compositions and methods for treating c-Kit associated disorders such as fibrosis, and more particularly, to compositions containing humanized c-Kit antibodies. ... | 03/29/2011 |
| 7910707 | Anti-interferon-α antibodies The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the dia... | 03/22/2011 |
| 7910708 | Anti-IL13 human antibodies The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis,... | 03/22/2011 |
| 7888484 | Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the human... | 02/15/2011 |
| 7786274 | Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases This invention features an antibody specifically binding to human IL-20 (e.g., mAb 7E and a equivalent thereof) and its use in treating an IL-20 associated inflammatory disease, such as atherosclerosis, RA, psoriasis, psoriatic arthritis, bacteria-induced gastric ul... | 08/31/2010 |
| 7750126 | Antibodies that bind to a member of the IL-6/G-CSF/MGF family A full-length cDNA corresponding to an EST (AA418955), which does not show any homology to other proteins in the database but has a weak homology to G-CSF, has been successfully isolated by synthesizing primers based on the EST sequence, and effecting PCR-cloning fr... | 07/06/2010 |
| 7741450 | Antibodies to GM-CSF Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. T... | 06/22/2010 |
| 7741449 | Anti-interferon alpha antibodies The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity o... | 06/22/2010 |
| 7737259 | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided. ... | 06/15/2010 |
| 7659378 | Hepatocyte growth factor (HGF) binding antibody The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic a... | 02/09/2010 |
| 7655763 | Neutralizing antibodies against GDF-8 and uses therefor The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagno... | 02/02/2010 |
| 7635760 | Anti-myostatin antibodies A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates... | 12/22/2009 |
| 7632926 | Humanized monoclonal antibodies to hepatocyte growth factor The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. ... | 12/15/2009 |
| 7608694 | Antibody molecules having specificity for human IL-1β The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. ... | 10/27/2009 |
| 7534870 | Stable pharmaceutical composition comprising erythropoietin The present invention provides a new stable pharmaceutical composition of erythropoietin (EPO) that is stabilized with a combination of a poloxamer polyol and a polyhydric alcohol. ... | 05/19/2009 |
| 7504485 | Human antibodies that bind human IL-12 Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can... | 03/17/2009 |
| 7491804 | DNA dependent protein kinase catalytic subunit phosphorylation sites and antibodies thereto The identification and use of two major DNA-PKcs autophosphorylation sites. Threonine (T) 2609 and Serine (S) 2056, including antibodies specific for phosphorylated T2609 and 52056. Peptides and polynucleotides encoding same, that feature these two sites of phosphor... | 02/17/2009 |
| 7446181 | Antibodies that bind human Dickkopf-1 proteins The invention relates to antibodies and immunologically active portions thereof that selectively bind a human Dickkopf-1 (Dkk-1) or Dkk-1-related polypeptide, and to compositions that contain such antibodies and/or immunologically active portions. ... | 11/04/2008 |
| 7435799 | TNF-α binding molecules The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation... | 10/14/2008 |
| 7435800 | Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation Antibody to human IL-20 protein, a method for generation thereof and cells producing this antibody are disclosed. The antibody of the present invention has specificity to neutralizing hIL-20W-induced CPAE proliferation activity, and is useful for treating IL-20-indu... | 10/14/2008 |
| 7431927 | TNFα-neutralizing antibodies The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monocl... | 10/07/2008 |
| 7432360 | Multi-dose erythropoietin formulations The present invention is directed to multi-dose erythropoietin formulations for parenteral administrations. The formulations contain one or more of the following preservatives benzethonium chloride, phenoxyethanol and phenylethyl alcohol. ... | 10/07/2008 |
| 7427471 | Modified “S” antibodies The invention relates to the field of antibodies, and particularly to modified antibodies, methods of preparing modified antibodies and uses thereof. More particularly, the invention relates to the preparation of more active IgG antibodies by the addition of an extr... | 09/23/2008 |
| 7425330 | Methods of inhibiting TNFα activity in the blood of a patient Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 09/16/2008 |
| 7423129 | Antibodies to human eotaxin The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further ... | 09/09/2008 |
| 7416729 | Methods of treating rheumatoid arthritis with anti-TNF antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 08/26/2008 |
| 7411049 | Hybridoma cell lines and monoclonal antibodies recognizing Prox1 Monoclonal antibodies to Prox1 of vertebrates (pfam05044.5; NM_002763.3) and two continuous cell lines for their production are disclosed. These antibodies are particularly useful in immunoassays to detect the presence of Prox1 protein in vertebrate tissues and cell... | 08/12/2008 |
| 7405277 | Antibodies against monocyte chemotactic proteins The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same. ... | 07/29/2008 |
| 7404955 | Methods of inhibiting or neutralizing TNFα in patients with tissue injury Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 07/29/2008 |
| 7405274 | Connective tissue growth factor antibodies The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders as... | 07/29/2008 |
| 7402662 | Antibody molecules specific to human tumor necrosis factor alpha There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA ... | 07/22/2008 |
| 7396911 | Chimeric polypeptides containing chemokine domains This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof. ... | 07/08/2008 |
